| Literature DB >> 23799176 |
Soroush Sardari1, Kayhan Azadmanesh, Fereidoun Mahboudi, Asghar Davood, Ruhollah Vahabpour, Rezvan Zabihollahi, Hosna Gomari.
Abstract
BACKGROUND: Gp41 of HIV (Human Immunodeficiency Virus) is a protein that mediates fusion between viral and cellular membranes. The agent, T-20, which has been approved for HIV inhibition, can restrain Gp41 function in the fusion process; nevertheless, it has disadvantages like instability, high cost of production and injection form to be delivered twice a day.Entities:
Keywords: Antagonists and inhibitors; Drug design; Flow cytometry; HIV fusion inhibitors
Year: 2013 PMID: 23799176 PMCID: PMC3689560
Source DB: PubMed Journal: Avicenna J Med Biotechnol ISSN: 2008-2835
The structures and molecular weights of several compounds which used for in vitro test
|
|
Figure 1The interaction energy between NHR Gp41 and the tested compounds as measured by ArgusLab applications
In vitro result of testing compounds
| 1000 | 100 | 10 | 1 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||
| Average of infection ( | p-value | Inhibition ( | Average of infection ( | p-value | Inhibition ( | Average of infection ( | p-value | Inhibition ( | Average of infection ( | p-value | Inhibition ( | |
|
| 10.09 | 0.43205 | 3.90 | 10.39 | 7.5006E | -26.38 | 9.42 | 0.03761 | -14.58 | 9.71 | 0.0052 | -18.12 |
|
| 11.34 | 0.70266 | -8.07 | 9.98 | 0.00016 | -21.41 | 10.395 | 0.01178 | -25.45 | 9.80 | 0.0298 | -19.31 |
|
| 13.26 | 0.03129 | -25.33 | 6.48 | 0.000935 | 2117 | 6.3175 | 8.27E-05 | 23.14 | 6.37 | 0.0009 | 22.41 |
|
| 8.19 | 0.02335 | 21.95 | 6.33 | 5.37E | 2293 | 6.32 | 4.40E-05 | 2311 | 7.06 | 0.0300 | 34.08 |
|
| 9.36 | 0.35488 | 10.80 | 6.45 | 1.2205E | 2150 | 6.7675 | 0.000904 | 1757 | 6.93 | 0.0087 | 15.50 |
|
| -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.07 | 0.2151 | -9.54 |
|
| -- | -- | -- | 6.48 | 0.154259 | 1185 | 8.7225 | 0.04859 | -1851 | 8.41 | 0.1013 | -14.35 |
|
| -- | -- | -- | 7.07 | 0.629155 | 3.590 | 7.935 | 0.374156 | -7.81 | 7.74 | 0.4935 | -5.23 |
|
| -- | -- | -- | 7.31 | 0.933355 | 0.51 | 7.965 | 0.323508 | -8.22 | 8.41 | 0.1042 | -14.33 |
|
| -- | -- | -- | 7.57 | 0.674355 | 285 | 7.605 | 0.711123 | -3.32 | 8.69 | 0.0751 | -18.13 |
|
| -- | -- | -- | Dead | Dead | 8.47 | 0.039175 | -15.08 | 8.6 | 0.1772 | -15.84 | |
|
| -- | -- | -- | 7.61 | 0.682399 | -3.39 | 8.39 | 0.274113 | -13.99 | 8.60 | 0.0538 | -15.93 |
|
| 0.475 | 0.035355 | 93.54 | |||||||||
|
| -- | -- | -- | 6.16 | 0.000511 | 25 | -- | -- | -- | -- | -- | -- |
|
| 10.5 | -- | -- | 8.22 | -- | -- | -- | -- | -- | -- | -- | -- |
This test was done in triplicate and the average was normalized by the control group. Several compounds with inhibitory or stimulatory effect had good p-value. All concentration cannot be tested due to their solubility. BMS-806 used as a control test, NB-64 as a lead compound, and DMSO as a solvent control. Our new compounds are effective as lead compound
Figure 2NB64 RMSE superimposed over with; A) DAA-6; B) DAA-9 and C) DAA-12 RMSE values are 1.7158, 2.0479 and 1.6425, respectively, which indicate that they are similar in their 3-D structures
Figure 3The electrostatic surface of compounds; A) NB-64; B) DAA-6; C) DAA-9 and D) DAA-12. These compounds are similar in their electric surface
Figure 4This picture shows the docking between receptor (PDB ID: 1F23) and NB-2 by Hex application. Several involving amino-acids were marked by Hex